ES8702950A1 - Procedimiento para la obtencion purificada de un factor de inhibicion de la emigracion de macrofagos humanos - Google Patents

Procedimiento para la obtencion purificada de un factor de inhibicion de la emigracion de macrofagos humanos

Info

Publication number
ES8702950A1
ES8702950A1 ES543391A ES543391A ES8702950A1 ES 8702950 A1 ES8702950 A1 ES 8702950A1 ES 543391 A ES543391 A ES 543391A ES 543391 A ES543391 A ES 543391A ES 8702950 A1 ES8702950 A1 ES 8702950A1
Authority
ES
Spain
Prior art keywords
monoclonal antibodies
processes
human mif
cell lines
hybridoma cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES543391A
Other languages
English (en)
Other versions
ES543391A0 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Ciba Geigy AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Geigy AG filed Critical Ciba Geigy AG
Publication of ES8702950A1 publication Critical patent/ES8702950A1/es
Publication of ES543391A0 publication Critical patent/ES543391A0/es
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)

Abstract

METODO PARA LA PURIFICACION DE FACTORES HUMANOS DE INHIBICION DE LA MIGRACION DE MACROFAGOS HUMANOS Y DE SUS PROTEINAS. COMPRENDE LA PREPARACION DE UNA DISOLUCION QUE CONTIENE UN FACTOR DE INHIBICION DE LA MIGRACION DE MACROFAGOS HUMANOS, A PARTIR DE CULTIVOS CELULARES DE CELULAS MONONUCLEARES ESTIMULADAS Y CULTIVADAS CON CONCAVALINA A; ULTRACENTRIFUGACION Y CONCENTRACION DE LA MISMA; PUESTA EN CONTACTO DE LA DISOLUCION CONCENTRADA CON SOPORTES QUE CONTIENEN ANTICUERPOS MONOCLONALES ESPECIFICOS RESPECTO DE DICHO FACTOR; SEPARACION DE LAS PROTEINAS Y DE LAS DEMAS SUSTANCIAS NO LIGADAS; Y SEPARACION DEL FACTOR LIGADO A LOS ANTICUERPOS, MEDIANTE DISOCIACION SELECTIVA. ESTOS FACTORES TIENEN APLICACIONES FARMACOLOGICAS PARA LA DIAGNOSIS Y EL TRATAMIENTO DE ENFERMEDADES INMUNO-REGULADORAS E INFLAMATORIAS CRONICAS.
ES543391A 1984-05-24 1985-05-22 Procedimiento para la obtencion purificada de un factor de inhibicion de la emigracion de macrofagos humanos Expired ES8702950A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CH255784 1984-05-24
CH378684 1984-08-07
CH544684 1984-11-14
CH51285 1985-02-05

Publications (2)

Publication Number Publication Date
ES8702950A1 true ES8702950A1 (es) 1987-01-16
ES543391A0 ES543391A0 (es) 1987-01-16

Family

ID=27427909

Family Applications (3)

Application Number Title Priority Date Filing Date
ES543391A Expired ES8702950A1 (es) 1984-05-24 1985-05-22 Procedimiento para la obtencion purificada de un factor de inhibicion de la emigracion de macrofagos humanos
ES557071A Expired ES8801852A1 (es) 1984-05-24 1986-09-16 Procedimiento para la obtencion de anticuerpos monoclonales contra el factor de inhibicion de emigracion de macrofagos humanos.
ES557072A Expired ES8801850A1 (es) 1984-05-24 1986-09-16 Procedimiento para la obtencion de lineas celulares de hibridoma

Family Applications After (2)

Application Number Title Priority Date Filing Date
ES557071A Expired ES8801852A1 (es) 1984-05-24 1986-09-16 Procedimiento para la obtencion de anticuerpos monoclonales contra el factor de inhibicion de emigracion de macrofagos humanos.
ES557072A Expired ES8801850A1 (es) 1984-05-24 1986-09-16 Procedimiento para la obtencion de lineas celulares de hibridoma

Country Status (8)

Country Link
EP (1) EP0162812B1 (es)
JP (3) JPH0672158B2 (es)
AT (1) ATE93869T1 (es)
DE (1) DE3587553D1 (es)
DK (1) DK171646B1 (es)
ES (3) ES8702950A1 (es)
IE (1) IE60450B1 (es)
IL (1) IL75280A0 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8623850D0 (en) * 1986-10-03 1986-11-05 Ciba Geigy Ag Lymphokine related peptide
EP0263072B1 (en) * 1986-10-03 1994-03-23 Ciba-Geigy Ag Novel lymphokine related peptides
WO1990011301A1 (en) * 1989-03-17 1990-10-04 Genetics Institute, Inc. Human macrophage migration inhibitory factor
GB8915414D0 (en) * 1989-07-05 1989-08-23 Ciba Geigy Novel cytokines
US5107906A (en) * 1989-10-02 1992-04-28 Swenson Paul F System for fast-filling compressed natural gas powered vehicles
US5149544A (en) * 1989-11-13 1992-09-22 Research Corporation Technologies, Inc. Method of inhibiting progenitor cell proliferation
DE69435303D1 (de) * 1993-05-17 2010-09-02 Cytokine Pharmasciences Inc Er behandlung von krankheiten bei denen eine cytok
US6645493B1 (en) * 1993-05-17 2003-11-11 The Picower Institute For Medical Research Composition containing anti-MIF antibody
AU2001238677A1 (en) * 2000-02-28 2001-09-12 Idec Pharmaceuticals Corporation Method for preparing anti-mif antibodies
DE10121255A1 (de) 2001-04-30 2002-11-07 Switch Biotech Ag Verwendung von alpha 1-Antichymotrypsin Polypeptiden oder diese kodierende Nukleinsäuren, oder einer ein ACT Polypeptid oder diese kodierende Nukleinsäure exprimierende Zelle, zur Behandlung und/oder Prävention von diabetes-assoziierten und/oder arteriellen schlecht heilenden Wunden und zur Identifizierung von pharmakologisch aktiven Substanzen
UY27304A1 (es) 2001-05-24 2002-12-31 Avanir Pharmaceuticals Inhibidores del factor inhibidor de la migración de los macrófagos y métodos para su identificación
TW200418829A (en) 2003-02-14 2004-10-01 Avanir Pharmaceutics Inhibitors of macrophage migration inhibitory factor and methods for identifying the same
BRPI0609382A2 (pt) 2005-03-24 2010-03-30 Avanir Pharmaceuticals derivados da tienopiridinona como inibidores do fator inibitório de migração de macrófagos
CN100457895C (zh) * 2006-05-24 2009-02-04 中国科学院生物物理研究所 鼠抗人巨噬细胞迁移抑制因子单克隆抗体及其应用
WO2013050453A1 (en) * 2011-10-07 2013-04-11 Baxter Healthcare S.A. Oxmif as a diagnostic marker

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2755363C3 (de) * 1977-12-12 1983-12-01 R & Z Biologicals Beteiligungsgesellschaft mbH, 4050 Mönchengladbach Testverfahren zur Diagnose von Malignomen
US4299814A (en) * 1979-05-25 1981-11-10 Monsanto Company Radioimmunoassay of MIF
JPS5939832A (ja) * 1982-08-28 1984-03-05 Ajinomoto Co Inc モノクロ−ナル抗体ならびにその製法、使用法
DD230876A1 (de) * 1983-05-09 1985-12-11 Akad Wissenschaften Ddr Verfahren zur gewinnung monoklonaler antikoerper gegen human-mif

Also Published As

Publication number Publication date
ES557072A0 (es) 1987-08-01
IE60450B1 (en) 1994-07-13
DK171646B1 (da) 1997-03-03
ES557071A0 (es) 1988-02-16
JPH06217789A (ja) 1994-08-09
JPS60248617A (ja) 1985-12-09
IL75280A0 (en) 1985-09-29
EP0162812A3 (en) 1988-04-20
DK229985A (da) 1985-11-25
DE3587553D1 (de) 1993-10-07
IE851295L (en) 1985-11-24
ATE93869T1 (de) 1993-09-15
JPH0672158B2 (ja) 1994-09-14
DK229985D0 (da) 1985-05-23
ES8801852A1 (es) 1988-02-16
JPH0770192A (ja) 1995-03-14
JPH0780915B2 (ja) 1995-08-30
ES8801850A1 (es) 1987-08-01
EP0162812A2 (de) 1985-11-27
EP0162812B1 (de) 1993-09-01
ES543391A0 (es) 1987-01-16
JPH07108915B2 (ja) 1995-11-22

Similar Documents

Publication Publication Date Title
ES8801852A1 (es) Procedimiento para la obtencion de anticuerpos monoclonales contra el factor de inhibicion de emigracion de macrofagos humanos.
NO165556C (no) Monoklonale antistoff samt derivater derav med hoey affinitet til human-renin og sturkturelt lignende renin for in vitro anvendelse.
Van Damme et al. Separation and comparison of two monokines with lymphocyte-activating factor activity: IL-1 beta and hybridoma growth factor (HGF). Identification of leukocyte-derived HGF as IL-6.
Tomida et al. Purification of a factor inducing differentiation of mouse myeloid leukemic M1 cells from conditioned medium of mouse fibroblast L929 cells.
Yoshizaki et al. Induction of proliferation and Ig production in human B leukemic cells by anti-immunoglobulins and T cell factors.
Reinhold et al. Dipeptidyl peptidase IV (CD26) on human lymphocytes. Synthetic inhibitors of and antibodies against dipeptidyl peptidase IV suppress the proliferation of pokeweed mitogen-stimulated peripheral blood mononuclear cells, and IL-2 and IL-6 production
Koyasu et al. Production of interleukin 3 and gamma-interferon by an antigen-specific mouse suppressor T cell clone.
DK113389D0 (da) Monoklonale antistoffer
ATE245699T1 (de) Rekombinant pgp3, verfahren zu dessen herstellung,und dessen verwendung in der diagnose und therapie
Van Damme et al. Characterization of granulocyte chemotactic activity from human cytokine-stimulated chondrocytes as interleukin 8
Pancré et al. A suppressive lymphokine of platelet cytotoxic functions.
EP0265384A3 (en) Monoclonal antibodies to a colony stimulating factor
AU7151087A (en) Interferon-induced human protein in pure form, monoclonal antibodies thereto, and test kits containing these antibodies
NO174110C (no) Monoklonalt antistoff til anvendelse in vitro for diagnose av maligne tumor- eller akutte inflammasjonssykdommer, og som er spesifikt for N-acetyl-neuraminsyre i hybridom som produserer antistoffet
Shimokawa et al. Lymphocyte chemotaxis in inflammation. VII. Isolation and purification of chemotactic factors for T lymphocytes from PPD-induced delayed hypersensitivity skin reaction site in the guinea-pig.
Knudsen et al. Elevated intracellular cAMP levels inhibit interleukin-1 production by the tumour cell line U937
Kishimoto et al. Polymorphism of submandibular-sublingual salivary proteins which promote adhesion of Streptococcus mutans serotype-c strains to hydroxyapatite
ATE229983T1 (de) Maspin- ein neues serpin mit tumor unterdrückender aktivität
Kull Jr et al. Macrophage cytotoxin: Sources and mechanism
Booth et al. Interleukin-2 is required for the induction of erythrocyte-specific antibody responses in human lymphocyte cultures
JPH02282399A (ja) リンホカイン　ｓａｆ
Fontana et al. Can astrocytes and C6 glial cells substitute for macrophages by their production of IL-1?
Yodoi et al. Isotype-Specific Immunoglobulin Binding Factors of IgA and IgE
Fletcher NIH, Bethesda

Legal Events

Date Code Title Description
PC1A Transfer granted